

Table 9.26
All Lymphoid Neoplasms With Detailed Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2005-2011

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)		Percent (95% C.I.)		Percent (95% C.I.)	
Lymphoid Neoplasm	94,857	68.6 (68.2 , 69.0)	89.0 (88.0 , 89.9)		74.7 (74.2 , 75.2)		58.2 (57.5 , 59.0)	
1 Hodgkin Lymphoma	8,183	85.1 (84.1 , 86.0)	97.1 (95.7 , 98.1)		88.5 (87.5 , 89.4)		52.9 (48.6 , 57.0)	
1(a) Classical Hodgkin lymphoma	7,649	84.4 (83.3 , 85.3)	96.9 (95.3 , 97.9)		88.0 (86.9 , 89.0)		51.4 (47.0 , 55.6)	
1(a)1. Lymphocyte-rich/mixed cellularity/ lymphocyte-depleted	1,474	82.4 (79.7 , 84.7)	97.9 (93.3 , 99.4)		86.9 (84.2 , 89.2)		53.4 (44.6 , 61.5)	
1(a)1.1 Lymphocyte-rich	295	89.2 (83.3 , 93.1)	100.0 (- , -)		91.7 (85.2 , 95.4)		65.4 (42.4 , 81.1)	
1(a)1.2 Mixed cellularity	1,074	82.6 (79.5 , 85.2)	97.0 (90.5 , 99.1)		87.0 (83.8 , 89.7)		53.3 (42.7 , 62.9)	
1(a)1.3 Lymphocyte-depleted	105	60.8 (49.1 , 70.6)	- (- , -)		68.4 (54.2 , 79.0)		33.4 (12.8 , 55.6)	
1(a)2. Nodular sclerosis	4,346	89.3 (88.1 , 90.4)	96.9 (95.0 , 98.1)		91.5 (90.2 , 92.6)		55.8 (48.3 , 62.6)	
1(a)3. Classical Hodgkin lymphoma, NOS ^c	1,829	73.9 (71.3 , 76.3)	95.1 (87.6 , 98.1)		79.9 (77.1 , 82.3)		45.0 (38.1 , 51.7)	
1(b) Nodular lymphocyte predominant Hodgkin Lymphoma	534	94.9 (91.1 , 97.1)	100.0 (- , -)		95.8 (92.0 , 97.8)		75.9 (50.7 , 89.4)	
2 Non-Hodgkin lymphoma	84,404	67.5 (67.0 , 67.9)	87.0 (85.8 , 88.0)		73.1 (72.5 , 73.6)		58.9 (58.1 , 59.7)	
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	45	78.3 (57.7 , 89.7)	- (- , -)		75.5 (54.1 , 87.9)		- (- , -)	
4 Lymphoid neoplasm, NOS ^c	2,225	49.4 (46.7 , 52.0)	81.9 (63.9 , 91.4)		58.8 (55.2 , 62.3)		40.3 (36.3 , 44.3)	

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified.

- Statistic not displayed due to less than 25 cases.